Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
This is according to two studies of real-world use of the hepatitis C regimen.
Those who took the drug, which is included in Zepatier (grazoprevir/elbasvir), had a low rate of liver cancer during the following years.
A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.
Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
Genotype 3 of hepatitis C virus is typically difficult to treat.
More than 125,000 veterans will have received lifesaving cures by October 2018.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.
Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.